A 12-week open-label study with 3 within-patient double-blind placebo-controlled periods to evaluate the efficacy and safety of OraVescent fentanyl citrate treatment for the management of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain

Trial Profile

A 12-week open-label study with 3 within-patient double-blind placebo-controlled periods to evaluate the efficacy and safety of OraVescent fentanyl citrate treatment for the management of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2010

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 09 Nov 2007 Status changed from in progres to completed
    • 12 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top